ALS treatment resulted in a decrease in cyclin B1, CDK1, and cyclin E1 levels in both cell lines compared to the levels in untreated control cells, but it did not alter CDK2 levels (Figure 4C and 4E). The gene discussed is CDK2; the disease is amyotrophic lateral sclerosis.